Prognostic value of serum alanine aminotransferase on morbidity of primary liver cancer (A report of 95 780 cases)
刘通,王万超,陈思吟,陈悒存,姚楠,李文强,徐国帅,曲军
DOI: https://doi.org/10.3760/cma.j.cn115610-20201023-00671
2020-01-01
Abstract:Objective:To explore the prognostic value of serum alanine aminotransferase (ALT) on morbidity of primary liver cancer (hereinafter referred to as liver cancer).Methods:The retrospective cohort study was conducted. The data of 95 780 participants including 26 980 cases in the Kailuan General Hospital of North China University of Science and Technology, 18 306 cases in Kailuan Linxi Hospital, 14 469 cases in Kailuan Zhaogezhuang Hospital, 4 389 cases in Kailuan Tangjiazhuang Hospital, 4 561 cases in Kailuan Fan′gezhuang Hospital, 7 623 cases in Kailuan Jinggezhuang Hospital, 4 249 cases in Kailuan Lyujiatuo Hospital, 3 136 cases in Kailuan Linnancang Hospital, 6 356 cases in Kailuan Qianjiaying Hospital, 2 319 cases in Kailuan Majiagou Hospital and 3 392 cases in Kailuan Branch Hospital who participated health examination from July 2006 to December 2007 were collected. There were 76 491 males and 19 289 females, aged (51±11)years, with a range of 18-98 years. All the subjects were allocated into 3 groups according to tertiles of ALT, including 31 859 with ALT<14.7 U/L in the T1 group, 30 627 with 14.7 U/L≤ALT<22.0 U/L in the T2 group and 33 294 with ALT≥22.0 U/L in the T3 group. All participants received the same-order health examinations by the fixed team of doctors in 2006, 2008, 2010, 2012 and 2014 at the same place. Epidemiological investigation, anthropometric parameters and biochemical indicators were collected. Observation indicators: (1) comparisons of clinical characteristics among the 3 groups; (2) follow-up and morbidity of liver cancer; (3) risk factors analysis affecting new-onset liver cancer; (4) comparisons of the prognostic value of ALT on liver cancer model. Follow-up using physical examination was performed to detect new-onset liver cancer and survival up to December 31, 2015. The start time of follow-up was the first health examination in 2006 and the terminal event was new-onset liver cancer, loss of follow-up or death. Measurement data with normal distribution were expressed as Mean± SD, and comparisons among groups were analyzed using the one-way ANOVA. Measurement data with skewed distribution were described as M (range), and comparisons among groups were analyzed using the Kruskal-Wallis rank sum test. Count data were described as absolute numbers and (or) percentages, and comparisons among groups were analyzed using the chi-square test. The cumulative incidence of new-onset liver cancer was calculated by the Kaplan-Meier method, and comparisons of incidences among groups were done by the Log-rank test. Restrictive cubic spline regression was used to calculate the dose-response relation between the continuous ALT and the risks of new-onset liver cancer. The hazard ratio ( HR) and 95% confidence interval ( CI) of different levels of ALT on new-onset liver cancer were estimated by the COX proportional hazards regression models. The fitting degree of ALT on new-onset liver cancer model was calculated by the likelihood ratio test and akaike information criterion (AIC). The predictive power of different models was calculated using the C-statistics. Results:(1) Comparisons of clinical characteristics among the 3 groups: gender(male), age, systolic pressure, diastolic pressure, waistline, body mass index (BMI), total cholesterol (TC), triglyceride (TG), fasting blood glucose, high density lipoprotein cholesterol, low density lipoprotein, cases with positive Hepatitis B surface antigen (HBsAg), cases with hypertension, cases with diabetes, cases with cirrhosis, cases with fatty liver, cases with malignant tumor in immediate family, cases with smoking, cases with drinking, cases with physical exercise were 23 516, (53±14)years, (130±21)mmHg (1 mmHg=0.133 kPa), (82±12)mmHg, (85±10)cm, (24±3)kg/m 2, (4.9±1.1)mmol/L, 1.11 mmol/L (range, 0.79-1.63 mmol/L), (5.4±1.6)mmol/L, (1.5±0.4)mmol/L, (2.3±1.0)mmol/L, 478, 12 758, 2 482, 15, 5 899, 1 071, 9 553, 5 434, 5 210 in the T1 group, 24 886, (52±12) years, (132±21)mmHg, (84±12)mmHg, (87±10)cm, (25±3)kg/m 2, (4.9±1.2)mmol/L, 1.27 mmol/L(range, 0.91-1.90 mmol/L), (5.5±1.7)mmol/L, (1.6± 0.4)mmol/L, (2.4±0.9)mmol/L, 744, 13 884, 2 677, 13, 9 365, 981, 8 935, 5 216, 5 023 in the T2 group and 28 089, (50±12)years, (132±21)mmHg, (85±12)mmHg, (89±10)cm, (26±3)kg/m 2, (5.0±1.2)mmol/L, 1.45 mmol/L (range, 1.02-2.28 mmol/L), (5.6±1.8)mmol/L, (1.6±0.4)mmol/L, (2.3±0.9)mmol/L, 1 416, 15 471, 3 583, 70, 15 277, 1 350, 10 514, 6 184, 4 447 in the T3 group, showing significant differences among the three groups ( χ2=1 181.88, F=350.52, 148.39, 417.75, 948.63, 1 917.20, 111.60, χ2=3 747.25, F=133.78, 18.17, 14.45, χ2=478.33, 306.60, 181.38, 58.19, 5 649.18, 38.82, 45.69, 35.11, 152.64, P<0.05). (2) Follow-up and morbidity of liver cancer: all 95 780 participants were followed up for 9.05 years (range, 8.75-9.22 years). During the follow-up, there were 351 cases diagnosed with liver cancer. The total incidence density, incidence density in the female and male participants of liver cancer were 3.39/10 000 person-year, 1.11/10 000 person-year and 3.97/10 000 person-year, respectively. The incidence density of liver cancer was 2.09/10 000 person-year, 2.54/10 000 person-year, 5.42/10 000 person-year in the T1, T2, T3 groups, respectively. The cumulative incidence was 2.47‰, 3.10‰, 6.11‰ in the T1, T2, T3 groups, respectively, showing significant differences among the three groups ( χ2=63.50, P<0.05). (3) Risk factors analysis affecting new-onset liver cancer. Results of COX proportional hazards regression model analysis showed that comparison with T1 group, the incidence density of liver cancer was increased in the T3 group ( HR=1.87, 95% CI: 1.40-2.49, P<0.05) after adjustment of gender, age, BMI, TC, fasting blood glucose, positive HBsAg, hypertension, diabetes, liver cirrhosis, fatty liver, malignant tumor in immediate family, smoking, drinking, physical exercise. Results of restrictive cubic spline regression showed that continous ALT was nonlinear correlated with incidence of liver cancer, but showed a trend of rising curve (RCS_S1_ χ2=7.21, P<0.05). (4) Comparisions of the prognostic value of ALT on liver cancer model: a traditional multivariate model was established to incorporate factors such as gender, age, BMI, TC, fasting blood glucose, positive HBsAg, hypertension, diabetes, liver cirrhosis, fatty liver, malignant tumor in immediate family, smoking, drinking, physical exercise. The C statistic, -2Log L value and AIC value of this model were 0.791, 6 313.30 and 6 345.30 respectively. Then the ALT tertiles were grouped into the model to calculate the C statistic, -2Log L value and AIC value of the model at this time, which were 0.792, 6 300.48 and 6 328.48, respectively. The C statistic and AIC value of the multivariate + Fbg model decreased, and the difference between the -2Log L value of the multivariate model was 12.82, and the difference was statistically significant ( χ2=12.82, P<0.05). Conclusion:ALT is an independent risk factor for liver cancer and is an important reference indicator when establishing a predictive model of liver cancer or assessing the risk of liver cancer.